Vnitr Lek 2018, 64(3):309-313 | DOI: 10.36290/vnl.2018.042

More safe anticoagulant treatment - use of idarucizumab (Praxbind®): case reports from RE-VERSE AD study and clinical practice

David Tuček^1,*, Tomáš Veleta¹, Martin Havrda²

¹ Oddělení urgentní medicíny FN Hradec Králové

² I. interní klinika 3. LF UK a FN Královské Vinohrady, Praha

RE-VERSE AD, a prospective multicentric cohort study, examined the effect of idarucizumab on 2 cohorts of patients anticoagulated with dabigatran - in cohort A in patients with uncontrollable or life threatening bleeding, in cohort B in patients who undergo acute surgery. Within the study patients were intravenously administered 5 g antidote divided into 2 doses per 2.5 g within 15 min to eliminate the anticoagulation effect of dabigatran. A series of case studies is presented to describe the use of idarucizumab within the RE-VERSE AD study and in clinical practice in the period of 2015-2016 at the University Hospital Hradec Králové. The included examples illustrate the benefit of dabigatran as the only drug so far from the group of direct oral anticoagulants which has an antidote.

Keywords: antidote; bleeding; dabigatran; direct oral anticoagulants; DOAC; high risk of bleeding; idarucizumab; intervention

Received: May 29, 2017; Accepted: February 7, 2018; Published: March 1, 2018  Show citation